Bukwang Pharmaceutical Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bukwang Pharmaceutical Company Limited with three other
companies in this sector in South Korea:
Whanin Pharmaceutical Company Limited
sales of 147.95 billion Korean Won [US$137.30 million]
of which 78%
was Riperidon &Quetapin etc.),
Sam Chun Dang Pharm Co Ltd
(161.11 billion Korean Won [US$149.51 million]
JW Life Science Corp
(143.60 billion Korean Won [US$133.26 million]
During the year ended December of 2017, sales at
Bukwang Pharmaceutical Company Limited were 150.74 billion Korean Won (US$139.89 million).
increase of 8.7%
versus 2016, when the company's sales were 138.62 billion Korean Won.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Bukwang Pharmaceutical Company Limited had sales
of 147.53 billion Korean Won.